Dave Tudor PhD
Managing Director, Medicines Manufacturing Innovation Centre, Biologics & Quality.
Dave is the Managing Director of the Medicines Manufacturing Innovation Centre, Quality and Biologics.
The Medicines Manufacturing Innovation Centre is a collaboration between CPI, University of Strathclyde, UKRI, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.
The centre will ensure the UK is a technology and innovation leader in pharmaceutical manufacturing, thereby boosting the competitiveness of both sectors. The initial focus will be on technology translation for small molecule drug manufacture.
Dave also leads the Biologics business unit, CPI’s Quality function, which includes GMP obligations and CPI's PMO function.
Prior to joining CPI Dave worked for GSK. He joined the company in 1992 as a PhD Chemist from Glasgow University. He has over 20 years’ experience at GSK carrying out a number of Technical, Compliance and Manufacturing leadership roles. In 1997 he moved to Irvine to take up a lead chemist role before coming Quality Control Manager in 1998. He joined the site leadership team in 2001 to run Technical Development before moving to manufacturing as Actives Production Director in 2005.
During this time he completed a Masters degree in Manufacturing Leadership at Cambridge University. In 2007 he moved to GSK House to work on a central network re-structuring project before becoming Site Director at Montrose in October 2008. At Montrose, he led the transformation of the site to manufacture over 12 products for GSK including a major investment programme. In 2011 he was appointed VP Primary Supply Chain with responsibility for global Active Pharmaceutical Ingredients (API) manufacture and supply, a network of GMS sites across the world including facilities in Asia and Europe. In 2017 he was appointed VP Head of GMS Strategy with responsibility for manufacturing strategy, deployment of strategic programmes, performance management and advocacy.
He plays an active role with a number of Governments and is currently co-chair of the Life Sciences Scotland Industry Leadership Group.